Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.

Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Tubulis has raised series A funding to progress an ADC development platform invented at Leibniz Research Institute and Ludwig Maximillians University.

Forge is working on a gene therapy treatment invented at UPMC but has covered its bases by targeting viral vector production for third-party clients.

Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.

Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to 6 Dimensions Capital.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

CSPC returned for the anti-tumour therapy developer's series B round having backed its $147m series A early last year.

Frontier IP attracted $2.9m in a placement that will support its portfolio in responding to coronavirus-related challenges or opportunities.